v1
P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance
NobleIDNI4P84W09R04S88
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260521/CA2AB322)
ARK Inflections
Metadata Formats
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims